[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 12973
1. Raizer JJ, Koutcher JA, Abrey LE, Panageas KS, DeAngelis LM, Lis E, Xu S, Zakian KL: Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol; 2005 Jan;71(2):173-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is a highly aggressive tumor responsive to high-dose methotrexate based regimens.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / immunology. Immunocompetence. Lymphoma / diagnosis. Lymphoma / immunology. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Choline / metabolism. Creatine / metabolism. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Lactic Acid / metabolism. Lipid Metabolism. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Protons. Survival Analysis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Jan;21(1):84-93 [10669230.001]
  • [Cites] Radiology. 1993 Mar;186(3):745-52 [8430183.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):319-26; discussion 326-8 [10690720.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):292-8 [11981274.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1533-8 [8694522.001]
  • [Cites] Invest Radiol. 1997 May;32(5):288-96 [9140749.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] Radiology. 1995 Jan;194(1):271-6 [7997566.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1271-6 [11955739.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1485-9 [8694517.001]
  • [Cites] Can J Neurol Sci. 1998 Feb;25(1):13-22 [9532276.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] NMR Biomed. 2003 Feb;16(1):12-8 [12577293.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):915-28 [11429219.001]
  • [Cites] J Neurooncol. 1990 Oct;9(2):177-81 [2262803.001]
  • [Cites] Neuroradiology. 2001 Feb;43(2):169-77 [11326567.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1565-7 [8694527.001]
  • [Cites] Neurology. 2002 Nov 26;59(10):1557-62 [12451197.001]
  • [Cites] Curr Opin Oncol. 2000 May;12(3):199-204 [10841191.001]
  • [Cites] Science. 1982 Jun 18;216(4552):1325-7 [7079765.001]
  • [Cites] Radiology. 1995 Dec;197(3):649-54 [7480733.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):525-34 [9322843.001]
  • [Cites] NMR Biomed. 1999 Nov;12(7):413-39 [10654290.001]
  • [Cites] Magn Reson Med. 1990 Oct;16(1):1-8 [2255232.001]
  • [Cites] NMR Biomed. 2002 Oct;15(6):385-92 [12357552.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):306-18 [10690719.001]
  • [Cites] Radiology. 1995 Nov;197(2):525-31 [7480706.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):912-9; discussion 919-20 [12234397.001]
  • [Cites] Radiology. 1992 Dec;185(3):675-86 [1438744.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] J Neurooncol. 1993 Jul;17(1):27-35 [8120569.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):516-23 [9576546.001]
  • [Cites] Radiology. 1987 Oct;165(1):215-9 [3628774.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] Neuroradiology. 2000 Oct;42(10):738-41 [11110076.001]
  • (PMID = 15690135.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Protons; 30KYC7MIAI / Aspartic Acid; 33X04XA5AT / Lactic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Laudi N, Arora M, Burns L, McGlave P, Miller J, Bohac G, Rogers T, Barker J, Coad J, Weisdorf D: Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma. Am J Hematol; 2006 Jul;81(7):519-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma.
  • Conventional treatment of mantle cell lymphoma (MCL) yields modest responses and short remissions.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Mantle-Cell / therapy. Transplantation Conditioning
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Sepsis / etiology. Sepsis / mortality. Time Factors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755570.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Ekenel M, Iwamoto FM, Ben-Porat LS, Panageas KS, Yahalom J, DeAngelis LM, Abrey LE: Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer; 2008 Sep 1;113(5):1025-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
  • BACKGROUND: The most effective treatment for a new diagnosis of primary central nervous system lymphoma is high-dose methotrexate (MTX)-based chemotherapy followed by whole-brain radiation therapy (WBRT).
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Combined Modality Therapy. Lymphoma, Non-Hodgkin / therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18618509.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Barrionuevo C, Zaharia M, Martinez MT, Taxa L, Misad O, Moscol A, Sarria G, Guerrero I, Casanova L, Flores C, Zevallos-Giampietri EA: Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):38-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru.
  • It is well known that extranodal NK/T-cell lymphoma (NK/TCL) nasal type clusters in Asian countries.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536305.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Minamimoto R, Tateishi U, Tomita N, Inayama Y, Omura-Minamisawa M, Tayama Y, Hata M, Kubota Y, Inoue T: F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma. Ann Nucl Med; 2010 Feb;24(2):115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma.
  • We experienced two cases of mucosa-associated lymphoid tissue (MALT) lymphoma arising at unusual locations and used F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) to evaluate their response to radiation therapy (RT).
  • A 62-year-old male with proven prostatic MALT lymphoma and a 43-year-old woman with proven duodenal MALT lymphoma had diffuse FDG uptake in the lesion.
  • FDG PET/CT is useful for indicating the treatment site in MALT lymphoma and in evaluation of therapeutic response following RT.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Positron-Emission Tomography. Rare Diseases / diagnosis. Rare Diseases / radiotherapy. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077163.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Nitsu N, Okamoto M, Miura I, Hirano M: Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci; 2009 Feb;100(2):233-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma.
  • Diffuse large B-cell lymphoma (DLBCL) has heterogeneous clinical, histological, and molecular features.
  • A total of 1864 consecutive patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group from 1998 to 2005.
  • [MeSH-major] Chromosomes, Human, Pair 8 / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038003.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


7. Srivastava N, Mishra N, Singh S: Erythematous indurated swelling on nose and upper lip. Cutaneous T cell lymphoma. Dermatol Online J; 2008;14(8):16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythematous indurated swelling on nose and upper lip. Cutaneous T cell lymphoma.
  • [MeSH-major] Erythema / etiology. Lip Neoplasms / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis. Nose Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Granuloma, Lethal Midline / diagnosis. Granulomatosis with Polyangiitis / diagnosis. Humans. Male. Nasal Obstruction / etiology. Neoplasm Staging


8. Gorsane I, Bourkhis L, Laatiri MA, Aloui S, Letaif A, Haouala F, Ben Dhia N, Frih A, Zakhama A, Elmay M, Skhiri H: [Acute renal failure caused by renal lymphoma. A case report]. Nephrol Ther; 2010 Apr;6(2):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute renal failure caused by renal lymphoma. A case report].
  • Acute renal failure, as the initial manifestation of lymphoma, has been reported only in a few cases.
  • A diagnosis of diffuse large B-cell type non-Hodgkin lymphoma was made.
  • However, investigations revealed the presence of two others sites of lymphoma: gastric and ophthalmic.
  • The patient's renal function and kidney size as well as the other lymphoma locations were normalized after the initiation of chemotherapy.
  • [MeSH-major] Acute Kidney Injury / etiology. Eye Neoplasms / diagnosis. Kidney Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Neoplasms, Multiple Primary / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD20 / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Diagnosis, Differential. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20299297.001).
  • [ISSN] 1872-9177
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Csomor J, Bognár A, Benedek S, Sinkó J, Fekete S, Krenács L, Matolcsy A, Reiniger L: Rare provisional entity: primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma in a young woman. J Clin Pathol; 2008 Jun;61(6):770-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare provisional entity: primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma in a young woman.
  • Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma is a rare and provisional entity, characterised by cutaneous involvement and aggressive clinical behaviour.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers / analysis. CD8-Positive T-Lymphocytes / immunology. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Immunophenotyping. Karyotyping. Translocation, Genetic. Treatment Failure. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505891.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


10. Adenipekun A, Abudus-Salam A, Elumele TN: Chemotherapy in the management of advanced gastointestinal non-Hodgkin's lymphoma complicated with entero-cutaneous fistula: a case report. Afr J Med Med Sci; 2005 Jun;34(2):199-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in the management of advanced gastointestinal non-Hodgkin's lymphoma complicated with entero-cutaneous fistula: a case report.
  • A case of gastrointestinal non-Hodgkin's lymphoma with entero-cutaneous fistula formation following incomplete tumor resection.
  • A case is made for conservative management of entero-cutaneous fistula complicating non- Hodgkin's lymphoma before any radical treatment is contemplated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Glucocorticoids / therapeutic use. Intestinal Fistula / complications. Lymphoma, Non-Hodgkin / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16749349.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


11. Lesesve JF, Fediuk T, Merseille JM, Braun F: EDTA-dependent lymphoagglutination in a patient with non-Hodgkin lymphoma. Int J Lab Hematol; 2007 Jun;29(3):221-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EDTA-dependent lymphoagglutination in a patient with non-Hodgkin lymphoma.
  • We report the case of a woman who developed artifactual agglutination of both normal and lymphoma cells in the context of an unusual primary cutaneous leg type B-cell non-Hodgkin's malignancy, raising the potential of misdiagnosis.
  • [MeSH-major] Agglutination / drug effects. Edetic Acid / pharmacology. Lymphocytes / drug effects. Lymphoma, B-Cell / physiopathology
  • [MeSH-minor] Adult. Female. Humans. Leg / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474901.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 9G34HU7RV0 / Edetic Acid
  • [Number-of-references] 8
  •  go-up   go-down


12. Koster A, van Krieken JH, Mackenzie MA, Schraders M, Borm GF, van der Laak JA, Leenders W, Hebeda K, Raemaekers JM: Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res; 2005 Jan 1;11(1):154-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased vascularization predicts favorable outcome in follicular lymphoma.
  • PURPOSE: In malignant lymphoma, angiogenesis has been associated with adverse outcome or more aggressive clinical behavior.
  • This correlation has been established in groups of patients with a large heterogeneity regarding lymphoma subtypes and treatment regimens.
  • The aim of this study is to investigate the significance of vascularization in patients with follicular lymphoma receiving uniform first-line treatment.
  • EXPERIMENTAL DESIGN: We assessed microvessel density (MVD) in pretreatment lymph node biopsies of 46 previously untreated patients with follicular lymphoma using anti-CD34 immunohistochemical staining and interactive quantification.
  • CONCLUSION: This study shows that in follicular lymphoma increased vascularization is associated with improved clinical outcome.
  • Furthermore, VEGF-A expression seems not to be involved in follicular lymphoma angiogenesis.
  • [MeSH-major] Lymphoma, Follicular / mortality. Lymphoma, Follicular / therapy. Neovascularization, Pathologic
  • [MeSH-minor] Adult. Antigens, CD34 / biosynthesis. Biopsy. Disease-Free Survival. Female. Humans. Immunohistochemistry. In Situ Hybridization. Interferon-alpha / metabolism. Lymph Nodes / pathology. Male. Microcirculation. Middle Aged. Prognosis. RNA / metabolism. Recombinant Proteins. Time Factors. Treatment Outcome. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671540.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / Vascular Endothelial Growth Factor A; 63231-63-0 / RNA; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


13. Kotoula V, Bobos M, Kostopoulos I, Kaloutsi V, Koletsa T, Karayannopoulou G, Papadimitriou CS: In situ detection of hTERT variants in anaplastic large cell lymphoma. Leuk Lymphoma; 2006 Aug;47(8):1639-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ detection of hTERT variants in anaplastic large cell lymphoma.
  • The expression of hTERT and its isoforms is difficult to assess in lymphoma tissues with the commonly used reverse transcription-polymerase chain reaction (RT-PCR) methods, because non-neoplastic lymphocytes expressing hTERT are always present in the lymphomatous infiltrates.
  • The present study aimed to investigate hTERT mRNA variants in anaplastic large cell lymphoma (ALCL) (n = 38) with in situ hybridization (ISH), along with the immunodetection of hTERT protein.
  • [MeSH-major] Genetic Variation. In Situ Hybridization / methods. Lymphoma, Large-Cell, Anaplastic / genetics. Telomerase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Lymphocytes / metabolism. Male. Middle Aged. Neoplasm Proteins / genetics. RNA, Messenger / analysis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966278.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


14. Chen BG, Yan WH, Meng ZF, Guo ZM, Zhu M, Li BL: [Expression of CD66c (CEACM6) in adult acute leukemia and its significance]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jun;27(6):370-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CD66c (CEACM6) in adult acute leukemia and its significance].
  • OBJECTIVE: To explore the expression of CD66c (CEACM6) in adult acute leukemia and its significance.
  • [MeSH-major] Antigens, CD / biosynthesis. Carcinoembryonic Antigen / biosynthesis. Cell Adhesion Molecules / biosynthesis. Leukemia, Myeloid, Acute / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. GPI-Linked Proteins. HL-60 Cells. Humans. K562 Cells. Male. Middle Aged. Neoplasm, Residual / metabolism. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147224.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CEACAM6 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / RNA, Messenger
  •  go-up   go-down


15. Novelli G, Rossi M, Ferretti G, Nudo F, Bussotti A, Mennini G, Novelli L, Ferretti S, Antonellis F, Martelli S, Berloco PB: Molecular adsorbent recirculating system treatment for acute hepatic failure in patients with hepatitis B undergoing chemotherapy for non-Hodgkin's lymphoma. Transplant Proc; 2005 Jul-Aug;37(6):2560-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular adsorbent recirculating system treatment for acute hepatic failure in patients with hepatitis B undergoing chemotherapy for non-Hodgkin's lymphoma.
  • We used the Molecular Adsorbent Recirculating System (MARS) (MARS Monitor; Teraklin AG, Rostock, Germany) to treat 5 HBsAg-positive lymphoma patients with acute hepatic failure due to chemotherapy despite lamivudine treatment.
  • [MeSH-major] Hepatitis B / complications. Liver Failure, Acute / therapy. Lymphoma, Non-Hodgkin / complications. Sorption Detoxification / methods
  • [MeSH-minor] Adult. Brain / radiography. Electroencephalography. Hemodynamics. Hepatitis B Surface Antigens / blood. Hepatitis B e Antigens / blood. Humans. Liver Function Tests. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182743.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B e Antigens
  •  go-up   go-down


16. Colasanti P, Cordedda M, Zanchini R, Spanò G, Maione F, Berruti V, Mozzillo R: A case of midline destructive lesions in a cocaine snorter mimicking Wegener's granulomatosis and nasal-type natural killer/T-cell lymphoma. G Ital Dermatol Venereol; 2010 Aug;145(4):556-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of midline destructive lesions in a cocaine snorter mimicking Wegener's granulomatosis and nasal-type natural killer/T-cell lymphoma.
  • [MeSH-minor] Adult. Diagnosis, Differential. Granulomatosis with Polyangiitis / diagnosis. Humans. Killer Cells, Natural. Lymphoma, T-Cell, Cutaneous / diagnosis. Male. Nose Neoplasms / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • MedlinePlus Health Information. consumer health - Cocaine.
  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20823800.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  •  go-up   go-down


17. Kuruvilla J, Pintilie M, Stewart D, Lachance S, Power M, Couture F, Xenocostas A, Voralia M, Couban S, Foley R: Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group. Bone Marrow Transplant; 2010 Jul;45(7):1253-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group.
  • [MeSH-minor] Adolescent. Adult. Canada / epidemiology. Humans. Middle Aged. Transplantation, Homologous. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19915625.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


18. Huang WT, Chuang SS, Huang CC, Lu CL, Eng HL: Primary diffuse large B-cell lymphoma of the gallbladder with cholelithiasis masquerading as acute cholecystitis: case report and literature review. N Z Med J; 2007;120(1251):U2470
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the gallbladder with cholelithiasis masquerading as acute cholecystitis: case report and literature review.
  • Primary non-Hodgkin lymphoma (NHL) of the gallbladder (GB-NHL) is exceedingly rare.
  • He received cholecystectomy under the preoperative diagnosis of acute cholecystitis with septic shock, while pathologic examination revealed cholelithiasis and diffuse large B-cell lymphoma without acute inflammation.
  • Mucosa-associated lymphoid tissue (MALT) lymphoma seems to carry a longer survival than non-MALT lymphomas.
  • [MeSH-major] Cholecystitis, Acute / diagnosis. Cholelithiasis / diagnosis. Cholelithiasis / etiology. Gallbladder Neoplasms / complications. Gallbladder Neoplasms / diagnosis. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cholecystectomy. Diagnosis, Differential. Fatal Outcome. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome


19. Chuang SS, Hsieh PP, Lu CL, Wang YH, Fu TY, Tseng HH: A clinicopathologic and molecular study of follicular lymphoma in Taiwan. Clin Lymphoma Myeloma; 2006 Jan;6(4):314-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathologic and molecular study of follicular lymphoma in Taiwan.
  • BACKGROUND: The clinicopathologic and molecular features of follicular lymphoma (FL) in Taiwan have not been well defined.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Gene Expression Regulation, Leukemic / genetics. Lymphoma, Follicular / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies. Taiwan

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507209.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Gao X, Xue Z, Xing J, Lee DY, Gottschalk SM, Heslop HE, Bollard CM, Wong ST: Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging. Acad Radiol; 2010 Apr;17(4):479-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging.
  • RATIONALE AND OBJECTIVES: Molecular imaging modalities such as positron emission tomography (PET)/computed tomography (CT) have emerged as an essential diagnostic tool for monitoring treatment response in lymphoma patients.
  • We applied LINA retrospectively to nine lymphoma patients enrolled in an immunotherapy clinical trial conducted at the Center for Cell and Gene Therapy, Baylor College of Medicine.
  • [MeSH-major] Algorithms. Image Interpretation, Computer-Assisted / methods. Lymphoma / diagnosis. Lymphoma / therapy. Pattern Recognition, Automated / methods. Positron-Emission Tomography / methods. Subtraction Technique. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AUR. Published by Elsevier Inc. All rights reserved.
  • [Cites] IEEE Trans Med Imaging. 1999 Aug;18(8):712-21 [10534053.001]
  • [Cites] Comput Med Imaging Graph. 2010 Jan;34(1):55-60 [19709855.001]
  • [Cites] J Nucl Med. 2003 Feb;44(2):224-39 [12571214.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S82-8 [12719922.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1200-9 [12902408.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Aug;22(8):1014-25 [12906255.001]
  • [Cites] Mol Imaging Biol. 2004 Jul-Aug;6(4):200-7 [15262235.001]
  • [Cites] J Nucl Med. 2004 Sep;45(9):1431-4 [15347707.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2004 Mar;26(3):402-7 [15376886.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10):1836-9 [7562051.001]
  • [Cites] Radiology. 2004 Nov;233(2):433-40 [15516617.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1225-39 [16000293.001]
  • [Cites] Br J Radiol. 2006 Jan;79(937):32-6 [16421402.001]
  • [Cites] Med Image Anal. 2006 Oct;10(5):740-51 [16887376.001]
  • [Cites] Br J Haematol. 2006 Nov;135(3):293-302 [17032175.001]
  • [Cites] Med Phys. 2007 Jan;34(1):55-62 [17278490.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2838-45 [17609424.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2007;10(Pt 2):319-26 [18044584.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2465-71 [18551347.001]
  • [Cites] Mol Imaging Biol. 2008 Nov-Dec;10(6):306-14 [18665425.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2008;11(Pt 2):989-97 [18982701.001]
  • [Cites] J Nucl Med. 2009 May;50 Suppl 1:1S-10S [19380403.001]
  • [Cites] J Nucl Med. 2009 May;50 Suppl 1:21S-30S [19380407.001]
  • [Cites] Mol Imaging Biol. 2009 Jul-Aug;11(4):269-74 [19326177.001]
  • [Cites] Ann Oncol. 2009 Sep;20(9):1543-7 [19474116.001]
  • [Cites] Med Image Anal. 2001 Jun;5(2):143-56 [11516708.001]
  • (PMID = 20060747.001).
  • [ISSN] 1878-4046
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA126752; United States / NCI NIH HHS / CA / P50 CA126752-01; United States / NCI NIH HHS / CA / P50 CA126752-02; United States / NCI NIH HHS / CA / P50 CA126752-03
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS169322; NLM/ PMC2846835
  • [Keywords] NOTNLM ; Lymphoma / PET/CT / longitudinal registration of serial images / quantitative evaluation of treatment outcomes
  •  go-up   go-down


21. Gathany AH, Hartge P, Davis S, Cerhan JR, Severson RK, Cozen W, Rothman N, Chanock SJ, Wang SS: Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. Cancer Causes Control; 2009 Oct;20(8):1291-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma.
  • OBJECTIVE: Sun exposure and sensitivity, including pigmentation, are associated with risk for non-Hodgkin lymphoma (NHL).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • [Cites] PLoS Genet. 2008 May;4(5):e1000074 [18483556.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):687-96 [11401920.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):802-10 [12920225.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D528-32 [14681474.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]
  • [Cites] Genes Dev. 1995 Jun 1;9(11):1377-87 [7797077.001]
  • [Cites] Nucleic Acids Res. 1995 Jun 25;23(12):2127-36 [7541907.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1283-94 [8657101.001]
  • [Cites] Genomics. 1996 Oct 15;37(2):229-33 [8921401.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1466-74 [16204696.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):773-82 [16767092.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):704-6 [16785887.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9771-80 [17018637.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Haematologica. 2007 Jul;92(7):960-9 [17606447.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • (PMID = 19396635.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / Intramural NIH HHS / / Z01 CP010158-08; United States / ONCHIT HHS / OC / N01-OC-71105; United States / NCI NIH HHS / PC / N01-PC-65064; United States / Intramural NIH HHS / / Z01 CP010158-07; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / PC / N01-PC-67009; None / None / / N01 PC065064
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4
  •  go-up   go-down


22. Hassan IB, Islam SI, Alizadeh H, Kristensen J, Kambal A, Sonday S, Bernseen RM: Acute leukemia among the adult population of United Arab Emirates: an epidemiological study. Leuk Lymphoma; 2009 Jul;50(7):1138-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia among the adult population of United Arab Emirates: an epidemiological study.
  • There is no published data regarding adult acute leukemia (AL) in the United Arab Emirates (UAE).
  • Our objectives were to determine the distribution and incidence of adult AL in UAE (nationals and non-nationals).
  • This epidemiological survey recovered 263 adult patients with AL diagnosed between January 2000 and December 2006 with a median age of 34 years.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Epidemiologic Studies. Female. Humans. Incidence. Male. Middle Aged. Population Groups. Sex Factors. United Arab Emirates / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19557635.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Martin P, Leonard JP, Coleman M, Furman RR: Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma; 2009 Jun;9(3):247-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis.
  • The infiltration of nonmalignant cells surrounding the Reed-Sternberg cells within the tumors of Hodgkin lymphoma (HL) might be central to the pathophysiology of the disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. HIV Infections / complications. HIV Infections / therapy. Hodgkin Disease / complications. Hodgkin Disease / therapy. Lymphoma, AIDS-Related / therapy. Remission Induction. Sepsis / complications
  • [MeSH-minor] Adult. Humans. Immunosuppressive Agents / therapeutic use. Immunotherapy / methods. Male. Middle Aged. Treatment Outcome


24. Nikgoo A, Mirafshariyeh SA, Kazeminajad B, Eshkevari PS, Fatemitabar SA: Burkitt's Lymphoma of maxillary sinuses: review of literature and report of bilateral case. J Oral Maxillofac Surg; 2009 Aug;67(8):1755-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's Lymphoma of maxillary sinuses: review of literature and report of bilateral case.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Maxillary Sinus Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD20 / analysis. Biopsy. Humans. Male. Neprilysin / analysis. Palatal Neoplasms / diagnosis. Radiography, Panoramic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615595.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 38
  •  go-up   go-down


25. Rizzatti EG, Falcão RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK, Zago MA: Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol; 2005 Aug;130(4):516-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways.
  • Microarray studies have revealed the differential expression of several genes in mantle cell lymphoma (MCL), but it is unknown which of these differences are dependent on the transformed MCL cell itself or on the tumour microenvironment.
  • [MeSH-major] Gene Expression Profiling. Intercellular Signaling Peptides and Proteins / genetics. Lymphoma, Mantle-Cell / genetics. Oligonucleotide Array Sequence Analysis. Phosphatidylinositol 3-Kinases / genetics. Signal Transduction / genetics. Transforming Growth Factor beta / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / genetics. B-Lymphocytes / metabolism. Case-Control Studies. Child. Child, Preschool. Female. Gene Frequency. Humans. Male. Middle Aged. Wnt Proteins

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098065.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Transforming Growth Factor beta; 0 / Wnt Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down


26. Martini M, Hohaus S, Petrucci G, Cenci T, Pierconti F, Massini G, Teofili L, Leone G, Larocca LM: Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. Am J Clin Pathol; 2008 Mar;129(3):472-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma.
  • An important pathogenetic mechanism in Hodgkin lymphoma (HL) is the interaction between the neoplastic and reactive cells mediated by a complex network of cytokines with activation of cytokine signal transduction (STAT) pathways.
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epstein-Barr Virus Infections. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Phosphorylation. Prognosis. Radiotherapy. Reed-Sternberg Cells / metabolism. Reed-Sternberg Cells / pathology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18285272.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / STAT5 Transcription Factor
  •  go-up   go-down


27. Carrera D, Bajén MT, Mora J, Ricart Y, Benítez A, Ferrán N, Guirao S, Fernández-Sevilla A, Martín-Comín J: [Clinical utility of fused 67Ga SPECT/CT scan images in patients with lymphoma]. Rev Esp Med Nucl; 2006 Jan-Feb;25(1):3-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical utility of fused 67Ga SPECT/CT scan images in patients with lymphoma].
  • AIM: The aim of this work is to show the clinical utility of the fused SPECT 67Ga/CT images in patients with lymphoma.
  • MATERIAL AND METHOD: 44 patients (22 male) with lymphoma have been studied.
  • 22 with Hodgkin's disease and 22 with non Hodgkin lymphoma.
  • CONCLUSION: To make fused SPECT 67Ga/CT images in patients with lymphoma allows improving the diagnostic precision in a 46% of the cases, mainly in the abdominal, bone and of the diaphragmatic area studies.
  • [MeSH-major] Gallium. Lymphoma / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Abdominal Neoplasms / radionuclide imaging. Adult. Aged. Aged, 80 and over. Bone Neoplasms / radionuclide imaging. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Esp Med Nucl. 2006 Mar-Apr;25(2):77-9 [16759612.001]
  • (PMID = 16540004.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; CH46OC8YV4 / Gallium
  •  go-up   go-down


28. Chelly I, Mekni A, Bellil K, Belhadj Salah M, Bellil S, Haouet S, Kchir N, Horchani A, Zitouna MM: [Testicular lymphoma: report of 4 cases]. Tunis Med; 2007 Oct;85(10):896-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular lymphoma: report of 4 cases].
  • BACKGROUND: Primary testicular lymphoma is the most common testicular malignancy in the elderly, account for 1% of all non Hodgkin lymphoma (NHL).
  • The aim was to report from new cases of testicular lymphoma CASES: We report the only four cases of testicular lymphoma observed in a period of 15 years; all these cases were primary diffuse large cell B NHL.
  • [MeSH-major] Lymphoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Necrosis. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236816.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


29. Bouaziz JD, Cordel N, Hickman G, Fieschi C, Ortonne N, Bagot M: Cutaneous tumor lysis syndrome in a patient with HTLV-1 adult T-cell lymphoma/leukemia. Blood; 2009 Nov 5;114(19):4320-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous tumor lysis syndrome in a patient with HTLV-1 adult T-cell lymphoma/leukemia.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Skin Diseases / pathology. Tumor Lysis Syndrome / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892727.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


30. Klabusay M, Lysák D, Hrabcáková V, Navrátil M, Coupek P, Mayer J: [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation]. Cas Lek Cesk; 2008;147(6):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
  • BACKGROUND: Peripheral blood stem cells are the preferred source for transplantation of hematopoiesis in patients with non-Hodgkin's lymphoma.
  • Authors analyzed the effect of two growth factors (leridistim and filgrastim) on the kinetics and phenotype of CD34+ cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Antigens, CD34 / analysis. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cell Mobilization. Interleukin-3 / pharmacology. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation. Recombinant Fusion Proteins / pharmacology
  • [MeSH-minor] Adult. Female. Filgrastim. Humans. Immunophenotyping. Leukapheresis. Leukocytes / immunology. Male. Middle Aged. Recombinant Proteins. Stem Cells / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724529.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Interleukin-3; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 193700-51-5 / leridistim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


31. Tanosaki R, Tobinai K: Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches. Expert Rev Hematol; 2010 Dec;3(6):743-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches.
  • Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection.
  • Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type.
  • Although the prognosis of chronic and smoldering-type ATL is relatively good, that of patients with acute- or lymphoma-type ATL still remains extremely poor.
  • [MeSH-major] Immunotherapy. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Interferon-alpha / therapeutic use. Kaplan-Meier Estimate. Stem Cell Transplantation. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21091150.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


32. Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B: A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol; 2010 Dec;63(6):984-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
  • BACKGROUND: Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma.
  • RESULTS: After 6 weeks of twice-weekly therapy, several concentrations of hypericin resulted in the significant improvement of treated skin lesions among the majority of patients with cutaneous T-cell lymphoma and psoriasis whereas the placebo vehicle was ineffective.
  • [MeSH-major] Light. Lymphoma, T-Cell, Cutaneous / drug therapy. Perylene / analogs & derivatives. Photochemotherapy / methods. Psoriasis / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Phototherapy / adverse effects. Placebos. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PERYLENE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20889234.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Placebos; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


33. Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y: Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci; 2009 Jan;100(1):54-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
  • It has been used to treat B-cell non-Hodgkin lymphoma (B-NHL), but recently rituximab resistance has been a cause for concern.
  • CD20 expression in lymphoma cells was evaluated by immunohistochemistry or flow cytometry.
  • Sixteen cases (27%) showed loss of CD20 expression with four histological patterns: pattern 1, no remarkable histological change (FL, 5; DLBCL, 3; and CLL, 2); pattern 2, proliferation of plasmacytoid cells (FL, 2; DLBCL, 1; and MZBCL, 1); pattern 3, transformation to classical Hodgkin's lymphoma (FL, 1); and pattern 4, transformation to anaplastic large cell lymphoma-like undifferentiated lymphoma (FL, 1).
  • In conclusion, B-NHL showed various histological and immunophenotypic changes after rituximab therapy, including not only CD20 loss but also proliferation of plasmacytoid cells or transformation to special subtypes of lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / analysis. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Immunophenotyping. Male. Middle Aged. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038008.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


34. Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, Dannaher C, Greco FA: Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma; 2009 Jun;9(3):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
  • PURPOSE: To evaluate the efficacy and safety of treatment with Yttrium-90 (90Y) ibritumomab tiuxetan following completion of short-course rituximab/chemotherapy in patients with previously untreated follicular non-Hodgkin lymphoma.
  • PATIENTS AND METHODS: Forty-one patients with previously untreated follicular lymphoma received rituximab for 4 consecutive weeks, followed by 3 cycles of rituximab combined with either CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone; 88%) or CVP (cyclophosphamide/ vincristine/prednisone; 12%).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Yttrium Radioisotopes / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Prednisolone. Prednisone / administration & dosage. Radioimmunotherapy / methods. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19525191.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; CHOP protocol; COP protocol 2; VAP-cyclo protocol
  •  go-up   go-down


35. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS: Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol; 2005 Apr 1;23(10):2208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
  • We report the incidence and outcome of solid tumors at 10-year follow-up in a large cohort of uniformly treated patients who underwent ABMT for non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Bone Marrow Transplantation. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasms / epidemiology. Neoplasms / etiology. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology. Whole-Body Irradiation / adverse effects
  • [MeSH-minor] Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Nov 1;23(31):8120-1; author reply 8121-2 [16258113.001]
  • (PMID = 15753460.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


36. Zhao XR, Ma DL: [Expression of Oct2 and its significance in lymphoma diagnosis]. Zhonghua Bing Li Xue Za Zhi; 2005 Jun;34(6):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Oct2 and its significance in lymphoma diagnosis].
  • OBJECTIVE: To investigate the specificity and sensitivity of Oct2 protein expression in lymphoma cells and its significance in diagnosis and classification of lymphoma.
  • METHODS: Formalin-fixed and paraffin-embedded materials from 129 cases of lymphoma and 10 cases of reactive lymphoid hyperplasia (RLH) were studied by EnVision immunohistochemistry for Oct2 protein.
  • It was diffusely expressed in B-cell lymphoma cells.
  • 97.7% cases (85/87) of B-cell lymphoma and 3.8% cases (1/26) of T-cell lymphoma were positive for Oct2 protein.
  • The expression rates of Oct2 protein in nodular lymphocyte-predominant Hodgkin lymphoma and classic Hodgkin lymphoma were 3/3 and 46.2% (6/13) respectively.
  • CONCLUSION: As a relatively sensitive and specific marker for B cells, Oct2 can serve as a useful antibody for the diagnosis and differential diagnosis of lymphoma.
  • [MeSH-major] Lymphoma / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, T-Cell / metabolism. Octamer Transcription Factor-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD20 / metabolism. Antigens, CD79 / metabolism. Child. Diagnosis, Differential. Female. Germinal Center / metabolism. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Male. Middle Aged. Pseudolymphoma / diagnosis. Pseudolymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185500.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / CD79A protein, human; 0 / Octamer Transcription Factor-2
  •  go-up   go-down


37. Mallant M, Hadithi M, Al-Toma AB, Kater M, Jacobs M, Manoliu R, Mulder C, van Waesberghe JH: Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J Gastroenterol; 2007 Mar 21;13(11):1696-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma.
  • AIM: To evaluate computed tomography (CT) findings, useful to suggest the presence of refractory celiac disease (RCD) and enteropathy associated T cell lymphoma (EATL).
  • [MeSH-major] Celiac Disease / radiography. Lymphoma, T-Cell / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Intestines / pathology. Intestines / radiography. Male. Mesentery / blood supply. Middle Aged. Organ Size. Radiography, Abdominal / methods. Spleen / pathology

  • Genetic Alliance. consumer health - Enteropathy-Associated T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Liver Dis. 2002 Sep;34 Suppl 2:S150-3 [12408460.001]
  • [Cites] Radiology. 1999 May;211(2):389-94 [10228518.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep 1;18(5):487-94 [12950421.001]
  • [Cites] Abdom Imaging. 2004 Jan-Feb;29(1):15-7 [15160747.001]
  • [Cites] Br J Radiol. 1980 Jun;53(630):532-7 [7426864.001]
  • [Cites] Gut. 1983 Mar;24(3):228-30 [6826107.001]
  • [Cites] AJR Am J Roentgenol. 1985 Feb;144(2):299-302 [3871273.001]
  • [Cites] Am J Gastroenterol. 1985 Jan;80(1):27-9 [3966450.001]
  • [Cites] Radiology. 1986 Mar;158(3):605-11 [3945730.001]
  • [Cites] Gastroenterology. 1986 Jun;90(6):2008-12 [3699417.001]
  • [Cites] AJR Am J Roentgenol. 1987 Jun;148(6):1129-32 [3495136.001]
  • [Cites] Radiographics. 1989 Nov;9(6):1045-66 [2685933.001]
  • [Cites] AJR Am J Roentgenol. 1991 Jan;156(1):23-32 [1898566.001]
  • [Cites] J Clin Gastroenterol. 1993 Jun;16(4):317-9 [8331266.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):200-3 [7904667.001]
  • [Cites] J Comput Assist Tomogr. 1995 Mar-Apr;19(2):319-20 [7890865.001]
  • [Cites] Baillieres Clin Gastroenterol. 1995 Jun;9(2):351-69 [7549031.001]
  • [Cites] Histopathology. 1995 Oct;27(4):349-54 [8847065.001]
  • [Cites] Eur Radiol. 2000;10(1):119-22 [10663727.001]
  • [Cites] Scand J Gastroenterol Suppl. 2000;(232):32-7 [11232488.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Sep;13(9):1123-8 [11564968.001]
  • [Cites] Int J Colorectal Dis. 2002 May;17(3):192-8 [12049314.001]
  • [Cites] Acta Paediatr Suppl. 1996 May;412:36-8 [8783753.001]
  • [Cites] Eur Radiol. 1997;7(2):246-8 [9038125.001]
  • [Cites] Radiology. 1999 Sep;212(3):853-60 [10478257.001]
  • [Cites] Dig Liver Dis. 2005 Jun;37(6):402-6 [15893278.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Jun;19(3):413-24 [15925846.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Sep;31(3):777-99 [12481731.001]
  • (PMID = 17461472.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4146948
  •  go-up   go-down


38. Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A: Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma; 2008 May;49(5):902-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept.
  • Follicular dendritic cells (FDCs) support the survival of follicular lymphoma (FL).
  • [MeSH-major] Immunoglobulin G / administration & dosage. Lymphoma, Follicular / drug therapy. Receptors, Tumor Necrosis Factor / administration & dosage. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Drug Delivery Systems / methods. Drug Monitoring. Etanercept. Humans. Middle Aged. Positron-Emission Tomography. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 May;49(5):837-8 [18464100.001]
  • (PMID = 18464109.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-102216; United States / NCI NIH HHS / CA / R21CA099324
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; OP401G7OJC / Etanercept
  •  go-up   go-down


39. Di Raimondo F, Caruso L, Bonanno G, Naso P, Chiarenza A, Fiumara P, Bari A, Palumbo GA, Russo A, Giustolisi R: Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? Ann Oncol; 2007 Feb;18(2):351-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?
  • BACKGROUND: Endoscopic ultrasound (EUS) is considered the best technique for locoregional staging at diagnosis but its role in the follow-up of patients with gastric lymphoma after organ-conserving strategies has not been established.
  • DESIGN AND METHODS: We retrospectively evaluated 23 patients with primary gastric lymphoma treated with a stomach-conservative approach.
  • Sixteen of them were affected by MALT lymphoma and seven by diffuse large-B-cell lymphoma (DLBCL).
  • CONCLUSIONS: Although the length of follow-up cannot exclude late relapse, we think that in restaging and follow-up of gastric lymphoma, EUS seems not to be a reliable tool if it is abnormal and E-Bx still remains the gold standard.


40. Yao HJ, Ying J, Wang Z, Yao DH, Ren XM, Bao YY: [One case report of primary penile malignant lymphoma (with a review of 24 case reports)]. Zhonghua Nan Ke Xue; 2006 Jun;12(6):520-4, 527
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One case report of primary penile malignant lymphoma (with a review of 24 case reports)].
  • OBJECTIVE: To investigate the early diagnosis and early treatment of primary penile malignant lymphoma.
  • METHODS: One case of rare primary penile malignant lymphoma was studied with regard to its primary clinical process and characteristics, differential diagnosis and therapeutic method.
  • CONCLUSION: Primary malignant lymphoma of the penis, though rare clinically, may be treated effectively if diagnosed early.
  • [MeSH-major] Lymphoma / diagnosis. Penile Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Early Diagnosis. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16833192.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


41. Tong H, Ren Y, Liu H, Xiao F, Mai W, Meng H, Qian W, Huang J, Mao L, Tong Y, Wang L, Qian J, Jin J: Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma; 2008 Jan;49(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome.
  • T-cell lymphoma-associated hemophagocytic syndrome (T-LAHS) has been frequently reported in Asian countries and is considered with extremely poor prognosis.
  • To summarize its clinical characteristics and explore its early diagnosis and treatment, we retrospectively analyzed the records of 113 patients with aggressive T cell lymphoma, of which 28 were associated with LAHS.
  • According to WHO classification (2001), 22 cases were classified into peripheral T-cell lymphoma (unspecified), 2 into extranodal NK/T-cell lymphoma, and 4 into systemic anaplastic large cell lymphoma.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203016.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


42. Arber DA, George TI: Bone marrow biopsy involvement by non-Hodgkin's lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol; 2005 Dec;29(12):1549-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow biopsy involvement by non-Hodgkin's lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens.
  • To evaluate the features of bone trephine biopsy involvement by non-Hodgkin lymphoma, 450 specimens were evaluated for percentage of marrow involvement, pattern of involvement, presence of germinal centers or follicular structures, and discordance with other involved sites.
  • Follicular grade 1 lymphoma (30.4%) was the most common type to involve the marrow, followed by diffuse large B-cell lymphoma (16.0%), mantle cell lymphoma (9.3%), low-grade B-cell lymphoma, not otherwise specified (8.7%), lymphoplasmacytic lymphoma (8.4%), follicular grade 2 lymphoma (7.1%), and mature T- and NK-cell lymphomas (6.4%).
  • Greater than 90% of follicular lymphomas had at least a focal paratrabecular infiltration pattern, but this pattern was also seen with other lymphoma types.
  • Interstitial disease infiltration tended to correlate with lymphoplasmacytic lymphoma but was also not specific.
  • The presence of germinal centers or follicular structures was associated with follicular lymphoma in 88% of cases.
  • Discordance between the bone marrow morphology and other tissue sites was observed in 24.9% of cases and was most often seen with follicular or diffuse large B-cell lymphoma.
  • Peripheral blood involvement by lymphoma was observed in 29% of cases, found in all disease groups except for follicular grade 3 lymphoma.
  • This study highlights the frequency of different lymphoma patterns in the marrow, limitations of primary lymphoma classification on biopsy material alone, and the relative frequency of marrow discordance and peripheral blood involvement by marrow lymphoma.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma / classification. Lymphoma / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Blood Cell Count / classification. Blood Cell Count / statistics & numerical data. Child. Child, Preschool. Female. Humans. Lymphocyte Count / classification. Lymphocyte Count / statistics & numerical data. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327427.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Djavanmardi L, Oprean N, Alantar A, Bousetta K, Princ G: Malignant non-Hodgkin's lymphoma (NHL) of the jaws: a review of 16 cases. J Craniomaxillofac Surg; 2008 Oct;36(7):410-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant non-Hodgkin's lymphoma (NHL) of the jaws: a review of 16 cases.
  • Non-Hodgkin's lymphoma (NHL) is rarely found in the jaw.
  • The therapy of this rare, diffuse, large cell lymphoma was very variable from one case to another but the majority of the patients were treated with a combination of chemotherapy and radiotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Mandibular Neoplasms / diagnosis. Maxillary Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Burkitt Lymphoma / diagnosis. Chemotherapy, Adjuvant. Child. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18562205.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


44. Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF: A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother; 2010 Feb-Mar;33(2):178-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
  • We evaluated the efficacy and safety of patient-specific immunotherapy with mitumprotimut-T idiotype keyhole limpet hemocyanin and granulocyte-monocyte colony-stimulating factor (GM-CSF) following rituximab in patients with follicular B-cell lymphoma.
  • Patients with previously untreated or relapsed/refractory CD20+ follicular lymphoma received 4 weekly infusions of rituximab and those with a complete response (CR), partial response (PR), or stable disease received mitumprotimut-T and GM-CSF injections subcutaneously.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Immunotherapy. Lymphoma, B-Cell / therapy. Lymphoma, Follicular / therapy. Recombinant Fusion Proteins / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Anti-Idiotypic / blood. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Antigens, CD20 / immunology. Antigens, Neoplasm / immunology. Disease-Free Survival. Female. Hemocyanin / genetics. Hemocyanin / immunology. Hemocyanin / metabolism. Humans. Immunity, Humoral / drug effects. Immunoglobulin Idiotypes / genetics. Immunoglobulin Idiotypes / immunology. Immunoglobulin Idiotypes / metabolism. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Rituximab

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145546.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / Immunoglobulin Idiotypes; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9013-72-3 / Hemocyanin; FV4Y0JO2CX / keyhole-limpet hemocyanin
  •  go-up   go-down


45. Koreishi AF, Saenz AJ, Persky DO, Cui H, Moskowitz A, Moskowitz CH, Teruya-Feldstein J: The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. Appl Immunohistochem Mol Morphol; 2010 May;18(3):206-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma.
  • Recent data suggests the presence of cytotoxic (TIA-1 and granzyme B+) and regulatory T-cells (FOXP3+) in classical Hodgkin lymphoma (cHL) tissues has been shown to correlate with poor overall survival in mainly diagnostic biopsies.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2000 Oct;10(5):345-50 [11100882.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):e5-6; author reply e7 [19470910.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1270-6 [11743050.001]
  • [Cites] Hum Pathol. 2002 Oct;33(10):968-74 [12395368.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Br J Haematol. 2004 Mar;124(5):645-52 [14871252.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):344-6 [15221373.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1376-82 [9028961.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5716-22 [16740709.001]
  • [Cites] Blood. 2006 Aug 1;108(3):804-11 [16861339.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4626-33 [16954517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13134-9 [17670934.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):958-65 [18024321.001]
  • [Cites] Swiss Med Wkly. 2007 Nov 17;137(45-46):625-34 [18027108.001]
  • [Cites] Clin Dev Immunol. 2007;2007:89195 [18317534.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3339-47 [18684866.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):528-36 [19017177.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Hematol Oncol. 2009 Mar;27(1):31-9 [18924115.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1470-6 [19224853.001]
  • [Cites] Immunity. 2009 May;30(5):613-5 [19464983.001]
  • [Cites] Immunity. 2009 May;30(5):626-35 [19464985.001]
  • [Cites] Immunity. 2009 May;30(5):636-45 [19464986.001]
  • [Cites] Immunity. 2009 May;30(5):646-55 [19464987.001]
  • [Cites] Immunity. 2009 May;30(5):656-65 [19464988.001]
  • [Cites] Blood. 2001 Feb 1;97(3):616-23 [11157476.001]
  • (PMID = 20065852.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009207; United States / NCI NIH HHS / CA / T32 CA009207-35
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Poly(A)-Binding Proteins; 0 / TIA1 protein, human; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ NIHMS324594; NLM/ PMC3260943
  •  go-up   go-down


46. Zhao WL, Liu YY, Plassa F, Jin XL, Wang L, Janin A, Shen ZX: [Analysis of overexpression of vascular endothelial growth factor-C in patients with angioimmunoblastic T-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2007 Oct;28(10):664-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of overexpression of vascular endothelial growth factor-C in patients with angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To explore the vascular endothelial growth factor-C (VEGF-C) expression and its clinical significance in malignant lymphoma.
  • METHODS: Lymphoma cells were isolated by laser microdissection.
  • VEGF-C expression in lymphoma tissue and microdissected lymphoma cells was measured by realtime quantitative PCR.
  • RESULTS: Comparing with that in 8 patients with reactive lymphocyte hyperplasia, VEGF-C was overexpressed in angioimmunoblastic T-cell lymphoma, both in lymphoma tissue (n = 18, P = 0.0020) and in microdissected lymphoma cells (n = 10, P < 0.0001).
  • CONCLUSION: The value of VEGF-C expression might be a biomarker of disease progression in angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / metabolism. Lymphoma, T-Cell / metabolism. Vascular Endothelial Growth Factor C / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399170.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


47. Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A, German Hodgkin Study Group: Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol; 2008 Jan 20;26(3):434-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
  • PURPOSE: Lymphocyte-predominant Hodgkin's lymphoma (LPHL) is rare and differs in histologic and clinical presentation from classical Hodgkin's lymphoma (cHL).
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Humans. Middle Aged. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Jul;5(7):368-9 [18542117.001]
  • (PMID = 18086799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Mani D, Guinee DG Jr, Aboulafia DM: AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: a diagnostic dilemma. World J Gastroenterol; 2008 Jul 21;14(27):4395-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: a diagnostic dilemma.
  • Plasmablastic lymphoma (PBL) is a rare form of diffuse large B-cell lymphoma characterized by weak/absent expression of conventional B-cell markers and strong expression of plasma cell markers.
  • [MeSH-major] Esophageal Neoplasms / complications. Esophageal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Medical Oncology / methods. Plasma Cells / pathology
  • [MeSH-minor] Adult. Antigens, CD20 / biosynthesis. Antigens, CD38 / biosynthesis. Cell Differentiation. Diagnosis, Differential. Endoscopy / methods. Gene Rearrangement. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Male. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Histopathology. 2007 Dec;51(6):774-7 [17944927.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):423-6 [11999580.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):41-6 [14707862.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1538-40; author reply 1540 [15489661.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Oncologist. 2006 Jun;11(6):666-73 [16794245.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):80-1 [17213349.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1358-61 [17577502.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1361-4 [17577503.001]
  • [Cites] Hepatology. 2007 Jul;46(1):107-12 [17526021.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3176-8 [17634499.001]
  • [Cites] AIDS Read. 2007 Sep;17(9):446-7 [17902226.001]
  • [Cites] AIDS Read. 2007 Sep;17(9):448-9 [17902227.001]
  • [Cites] Oral Dis. 2007 Nov;13(6):564-9 [17944673.001]
  • [Cites] Rev Soc Bras Med Trop. 2007 Sep-Oct;40(5):582-4 [17992417.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]
  • (PMID = 18666332.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.2.2.5 / Antigens, CD38
  • [Other-IDs] NLM/ PMC2731195
  •  go-up   go-down


49. Yokoyama H, Yamada MF, Ishizawa K, Yamamoto J, Tomiya Y, Harigae H, Kameoka J, Ichinohasama R, Sasaki T: Successful treatment of advanced extranodal NK/T cell lymphoma with unrelated cord blood transplantation. Tohoku J Exp Med; 2007 Apr;211(4):395-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of advanced extranodal NK/T cell lymphoma with unrelated cord blood transplantation.
  • Nasal natural killer (NK)/T cell lymphoma is a rare entity of non-Hodgkin's lymphoma which mostly occurs in East Asian countries.
  • Thus the prognosis of advanced NK/T cell lymphoma is generally poor, however, the promising results of allogeneic hematopoietic stem cell transplantation for advanced NK/T cell lymphoma have been recently reported.
  • We report here a case of a 36-year-old woman who was diagnosed as having an extranodal NK/T cell lymphoma, nasal type.
  • Cord blood thus could be an appropriate stem cell source for patients with advanced NK/T lymphoma who have no HLA matched donors.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Female. Histocompatibility Testing. Humans. Killer Cells, Natural / pathology. Nose Neoplasms / pathology. Nose Neoplasms / therapy. Tissue Donors

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409680.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Rossi M, Dastidar P, Pertovaara H, Järvenpää R, Luukkaala T, Kellokumpu-Lehtinen PL, Rautakunnas S, Heinonen T, Soimakallio S, Eskola H: Response analysis of non-hodgkin lymphoma using magnetic resonance imaging-based volumes. J Comput Assist Tomogr; 2009 May-Jun;33(3):466-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response analysis of non-hodgkin lymphoma using magnetic resonance imaging-based volumes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Image Interpretation, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Humans. Image Enhancement / methods. Middle Aged. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome. Young Adult


51. Basu D, Yaranal PJ, Kalyan K, Soundararaghavan J: Mantle cell lymphoma--a clinicopathological study of 13 cases. Malays J Pathol; 2005 Jun;27(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma--a clinicopathological study of 13 cases.
  • Mantle cell lymphoma is an uncommon non-Hodgkin's lymphoma.
  • In a period of four years, 13 cases of mantle cell lymphoma were diagnosed in our department, comprising 3.1% of all non-Hodgkin's lymphoma diagnosed.
  • Despite certain morphological similarity to other low-grade lymphomas, mantle cell lymphoma has a characteristic appearance of its own.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / immunology. Biopsy, Needle. Bone Marrow Examination. Cyclin D1 / immunology. Female. Humans. Immunohistochemistry. Immunophenotyping. Lymph Node Excision / statistics & numerical data. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676688.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antigens, CD20; 136601-57-5 / Cyclin D1
  •  go-up   go-down


52. Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M, EORTC-GELA H8 Trial Group: Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol; 2009 Dec;10(12):1160-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
  • BACKGROUND: Little is known about the longitudinal course of health-related quality of life (HRQoL) in patients with Hodgkin's lymphoma during their post-treatment follow-up and re-adaptation to normal life.
  • We report on the HRQoL of patients treated in the randomised H8 trial of the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
  • INTERPRETATION: HRQoL data after treatment for early-stage Hodgkin's lymphoma show that patients experience strain and limitations in all subdomains apart from cognitive functioning (QLQ-C30), and also have reduced motivation (MFI-20).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Dec;10(12):1134-5 [19959071.001]
  • (PMID = 19828373.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00379041
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Jing HM, Ke XY, Dong F: [Analysis of prognostic correlated factors of 49 patients with mucosa-associated lymphoid tissue lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec;15(6):1293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of prognostic correlated factors of 49 patients with mucosa-associated lymphoid tissue lymphoma].
  • The aim of this study was to investigate the clinical feature of mucosa-associated lymphoid tissue lymphoma and clarify the relationship between the pathological, clinical features, the expression of API2-MALT1 and the prognosis.
  • A number of factors including pathological characters, grade, stage, prognosis and treatment of 49 cases of MALT lymphoma were analyzed, and the API2-MALT1 rearrangement was detected by RT-PCR.
  • The results showed that 49 patients were diagnosed as MALT lymphoma, in which median age was 52.4 years.
  • Among 18 patients with gastric MALT lymphoma, 9 cases (50.0%) were helicobacter pylori (HP) positive and received antibiotic treatment.
  • It is concluded that MALT lymphoma is often seen in older patients, most of them were in low grade with slow progression.
  • The site, grade, stage and molecular genetic changes are important prognostic factors, which can contribute to choosing suitable treatment for patients with MALT lymphoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088487.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


54. Zhang PH, Zhou XY, Shui RH, Zhang TM, Zheng AH, Guo XH, Zhu XZ: [Detection of t (14; 18) chromosomal translocation in paraffin-embedded tissues of follicular lymphoma and its clinical significance]. Zhonghua Bing Li Xue Za Zhi; 2007 Sep;36(9):600-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of t (14; 18) chromosomal translocation in paraffin-embedded tissues of follicular lymphoma and its clinical significance].
  • OBJECTIVE: To study the genetic aberrations and their pathologic significance in follicular lymphoma (FL).
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Lymphoma, Follicular / genetics. Translocation, Genetic
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Female. Humans. In Situ Hybridization, Fluorescence / methods. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Male. Middle Aged. Paraffin Embedding. Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070448.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins
  •  go-up   go-down


55. Kurzwelly D, Müller CA, Korfel A, Thiel E, Linnebank M, Weller M, Herrlinger U: Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients. J Neurooncol; 2008 Oct;90(1):53-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients.
  • The aim of the present study was to evaluate a potential association of HLA class I and II alleles with primary central nervous system lymphoma (PCNSL) in immunocompetent patients.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Genetic Predisposition to Disease. Histocompatibility Antigens Class I / genetics. Histocompatibility Antigens Class II / genetics. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials, Phase IV as Topic. European Continental Ancestry Group. Female. Germany. Humans. Male. Middle Aged. Multicenter Studies as Topic

  • COS Scholar Universe. author profiles.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10 (5):1125-34 [8880200.001]
  • [Cites] Br J Dermatol. 2001 Dec;145(6):974-80 [11899152.001]
  • [Cites] J Neurooncol. 2001 May;52(3):253-61 [11519856.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] Dis Colon Rectum. 1999 Jan;42(1):66-70 [10211522.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1969-71 [15138479.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):229-38 [11265232.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2077-86 [10595937.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):617-22 [9554445.001]
  • [Cites] Tissue Antigens. 2001 Sep;58(3):166-70 [11703824.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1438-42 [14693734.001]
  • [Cites] Neurosurg Rev. 1994;17(3):211-5 [7838400.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):879-87 [8922295.001]
  • (PMID = 18587537.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II
  •  go-up   go-down


56. Au WY, Lo JY: HTLV-1-related lymphoma in Hong Kong Chinese. Am J Hematol; 2005 Jan;78(1):80-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1-related lymphoma in Hong Kong Chinese.
  • [MeSH-major] Asian Continental Ancestry Group. Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / ethnology
  • [MeSH-minor] Adult. Blood Donors / statistics & numerical data. Female. Hong Kong / epidemiology. Humans. Incidence. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609285.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


57. Trisolini R, Cancellieri A, Forti Parri SN, Poletti V, Boaron M, Patelli M: Hemoptysis and progressive dyspnea in a 39-year-old woman with previous sinonasal lymphoma. Respiration; 2006;73(2):253-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemoptysis and progressive dyspnea in a 39-year-old woman with previous sinonasal lymphoma.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunoglobulin kappa-Chains / blood. Lymphoma, B-Cell / drug therapy. Neoplasm Recurrence, Local / therapy. Paranasal Sinus Neoplasms / drug therapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Dyspnea.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205049.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


58. Seker M, Ustaalioğlu BB, Bilici A, Yildirim ME, Kefeli U, Barisik NO, Tamer I, Gumus M: Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma. Leuk Res; 2010 Jul;34(7):e160-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antiviral Agents / therapeutic use. Drug Administration Schedule. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / drug therapy. Humans. Immunophenotyping. Lamivudine / therapeutic use. Male. Remission Induction. Reverse Transcriptase Inhibitors / therapeutic use. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219245.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 23
  •  go-up   go-down


59. Shaminie J, Peh SC, Tan J: p53 alterations in sequential biopsies of Asian follicular lymphoma: a study of immunohistochemical staining pattern and gene mutations by PCR-SSCP in paraffin-embedded tissues. Pathology; 2005 Feb;37(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 alterations in sequential biopsies of Asian follicular lymphoma: a study of immunohistochemical staining pattern and gene mutations by PCR-SSCP in paraffin-embedded tissues.
  • Although p53 mutations are less commonly present in haematological malignancies when compared with other solid tumours, they have been reported in histological transformation of follicular lymphoma.
  • [MeSH-major] Lymphoma, Follicular / genetics. Lymphoma, Follicular / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Mutation. Paraffin Embedding. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875732.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


60. Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, Lin TY, Huang HQ, Xia ZJ, Guan ZZ: High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer; 2007 Apr 1;109(7):1360-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers.
  • BACKGROUND: The authors investigated the prevalence of hepatitis B virus (HBV) infection by using serologic markers in non-Hodgkin lymphoma (NHL) compared with other types of cancers in Chinese patients.
  • [MeSH-major] Hepatitis B / epidemiology. Hepatitis B virus / isolation & purification. Lymphoma, B-Cell / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Viral / blood. Case-Control Studies. China / epidemiology. Enzyme-Linked Immunosorbent Assay. Female. Hepatitis B Surface Antigens / blood. Humans. Incidence. Lymphoma, T-Cell / virology. Male. Middle Aged. Prevalence


61. Cooper PB, Auerbach A, Aguilera NS, Adair C, Moores L, Geyer D, Rushing EJ: Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature. Clin Neuropathol; 2006 Sep-Oct;25(5):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature.
  • OBJECTIVE AND IMPORTANCE: Isolated anaplastic large cell lymphoma (ALCL) presenting in the primary central nervous system is distinctly uncommon.
  • Immunohistochemical staining revealed CD-30 and ALK-positivity typical of ALCL, a rare form of T-cell lymphoma.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Glioma / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Radiotherapy. Seizures / etiology


62. Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, Heerema NA, Lones MA, Harrison L, Cairo MS, Sanger WG: An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol; 2010 Feb;148(4):600-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.
  • Burkitt lymphoma (BL), an aggressive B-cell malignancy, is often curable with short intensive treatment regiments.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1981 Jun;3(4):307-15 [7260888.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Ann Genet. 1989;32(1):26-32 [2751244.001]
  • [Cites] Cytogenet Cell Genet. 1989;52(3-4):136-8 [2630185.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Nov;1(2):115-8 [2487150.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Oct 1;63(1):22-4 [1423221.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6547-52 [1330296.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Apr;6(4):199-205 [7685621.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):282-7 [7519050.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2463-73 [9395242.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):1-19 [9720711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1084-92 [16862570.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1925-30 [10706856.001]
  • [Cites] Blood Rev. 2001 Mar;15(1):49-59 [11333138.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5595-610 [11607812.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Eur J Haematol. 2003 Sep;71(3):179-83 [12930318.001]
  • [Cites] Leukemia. 2003 Oct;17(10):2016-24 [14513052.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):10-8 [15034863.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Mar;26(3):169-78 [15125609.001]
  • [Cites] J Pathol. 2004 Aug;203(4):940-5 [15258997.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):965-9 [15291356.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1595-603 [15370211.001]
  • [Cites] Int J Cancer. 1977 Apr 15;19(4):482-6 [844916.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Leukemia. 2009 Feb;23(2):323-31 [19020548.001]
  • [Cites] Eur J Cancer. 1981 May;17(5):577-84 [6271555.001]
  • (PMID = 19895612.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS163764; NLM/ PMC2921871
  •  go-up   go-down


63. Zane C, Venturini M, Sala R, Calzavara-Pinton P: Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed; 2006 Oct;22(5):254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma.
  • BACKGROUND: Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL).
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948827.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 22
  •  go-up   go-down


64. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R, AIDS Malignancy Consortium: Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood; 2010 Apr 15;115(15):3008-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
  • Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL).
  • We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV / physiology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / virology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prednisone / therapeutic use. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Vincristine / therapeutic use


65. Christou L, Kalambokis G, Bai M, Kamina S, Tsianos EV: Splenic marginal zone lymphoma in a patient with chronic hepatitis B. J Gastrointestin Liver Dis; 2009 Dec;18(4):511-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic marginal zone lymphoma in a patient with chronic hepatitis B.
  • [MeSH-major] Hepatitis B, Chronic / complications. Lymphoma, B-Cell, Marginal Zone / virology. Splenic Neoplasms / virology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Chemotherapy, Adjuvant. Humans. Male. Risk Factors. Splenectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Gastrointestin Liver Dis. 2010 Mar;19(1):118. Christou, Leonidas [added]; Kalambokis, Georgios [added]; Bai, Maria [added]; Kamina, Sevasti [added]
  • (PMID = 20076834.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Romania
  •  go-up   go-down


66. Yao B, Li YX, Song YW, Jin J, Liu YP, Wang WH, Wang SL, Sun YT, Yu ZH, Liu XF: [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity]. Zhonghua Zhong Liu Za Zhi; 2006 Jan;28(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
  • OBJECTIVE: The optimal treatment for primary non-Hodgkin's lymphoma (NHL) of the nasal cavity remains controversial.
  • 116 patients were morphologically diagnosed as having nasal NK/T cell lymphoma.
  • The immunophenotype was available in 57 cases and 52 (91.2%) of them were confirmed as NK/T-cell lymphoma.
  • The addition of chemotherapy to radiotherapy did not improve the survival of patients with early stage nasal lymphoma.
  • Radiotherapy is suggested as the primary treatment for stage I(E) and II(E) nasal NK/T cell lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Killer Cells, Natural. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Particle Accelerators. Prednisone / administration & dosage. Radiotherapy, High-Energy. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737624.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


67. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol; 2005 Oct 20;23(30):7614-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
  • PURPOSE: Bleomycin pulmonary toxicity (BPT) has been well described in Hodgkin's lymphoma (HL) patients treated with bleomycin-containing chemotherapy regimens.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Bleomycin. Child. Dacarbazine. Doxorubicin. Female. Granulocyte Colony-Stimulating Factor. Humans. Male. Middle Aged. Neoplasm Staging. Risk Factors. Survival Rate. Treatment Outcome. Vinblastine

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186594.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


68. Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H: Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol; 2006 Nov;142(5):883-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma.
  • PURPOSE: To investigate whether intravitreal methotrexate could be safely administered and improve vision in patients with ocular disease other than primary central nervous system lymphoma (PCNSL).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Injections. Lymphoma / drug therapy. Male. Middle Aged. Retrospective Studies. Visual Acuity. Vitreous Body

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056381.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


69. Hamaki T, Kami M, Kanda Y, Yuji K, Inamoto Y, Kishi Y, Nakai K, Nakayama I, Murashige N, Abe Y, Ueda Y, Hino M, Inoue T, Ago H, Hidaka M, Hayashi T, Yamane T, Uoshima N, Miyakoshi S, Taniguchi S: Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant; 2005 Mar;35(6):549-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Graft Survival. Graft vs Host Disease. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Survival Analysis. Transplantation Conditioning / methods. Treatment Outcome


70. Isoardo G, Campa E, Migliaretti G, Troni W: Incidence of paraneoplastic polyneuropathies associated with non-Hodgkin lymphoma in the province of Asti, Italy. J Neurol; 2007 Sep;254(9):1302-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of paraneoplastic polyneuropathies associated with non-Hodgkin lymphoma in the province of Asti, Italy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Paraneoplastic Polyneuropathy / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Female. Humans. Incidence. Italy / epidemiology. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 1995 Oct;118 ( Pt 5):1233-45 [7496783.001]
  • [Cites] Eur J Neurol. 2001 Mar;8(2):157-65 [11284994.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40 [15258215.001]
  • [Cites] Arch Neurol. 1998 Jul;55(7):981-4 [9678316.001]
  • [Cites] Acta Neurol Scand. 2004 Mar;109(3):188-93 [14763956.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1971 Feb;34(1):42-50 [4323973.001]
  • [Cites] Acta Neurol Scand. 1991 Jan;83(1):45-51 [1849335.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1997 Dec;63(6):706-18 [9416801.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1993 Oct;56(10):1066-71 [7691991.001]
  • [Cites] Muscle Nerve. 2001 Sep;24(9):1197-201 [11494273.001]
  • (PMID = 17260172.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Germany
  •  go-up   go-down


71. Pasricha SR, Grigg A, Catalano J, Leahy M, Underhill C, Arthur C, D'Rozario J, Lowenthal R, Reed K, Spencer A: A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer; 2008 Dec 1;113(11):3192-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.
  • BACKGROUND: Administration of salvage chemotherapy to patients with relapsed or refractory lymphoma is associated with significant toxicity.
  • We present a phase 2 study of vinorelbine and gemcitabine with or without ifosfamide administered in an ambulatory care setting for relapsed or refractory lymphoma.
  • CONCLUSIONS: Vinorelbine-based and gemcitabine-based chemotherapy is effective in the salvage setting against lymphoma and can be administered in an ambulatory setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recurrence. Risk. Salvage Therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society
  • (PMID = 18932253.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


72. Kelemen K, Braziel RM, Gatter K, Bakke TC, Olson S, Fan G: Immunophenotypic variations of Burkitt lymphoma. Am J Clin Pathol; 2010 Jul;134(1):127-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic variations of Burkitt lymphoma.
  • Burkitt lymphoma (BL) exhibits a characteristic immunophenotype that is positive for pan-B-cell antigens and CD10 and expresses clonal surface immunoglobulins (SIgs).
  • [MeSH-major] Burkitt Lymphoma / immunology. Immunophenotyping. Lymphoma, AIDS-Related / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Chromosome Aberrations. Female. Flow Cytometry. Humans. Immunoglobulin kappa-Chains / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Remission Induction. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551277.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


73. Cingolani A, Torti L, Pinnetti C, de Gaetano Donati K, Murri R, Tacconelli E, Larocca LM, Teofili L: Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. AIDS; 2010 Sep 24;24(15):2408-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma.
  • In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center.
  • [MeSH-minor] Adult. Aged. Drug Interactions. Female. Humans. Male. Middle Aged


74. Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol; 2005 Jul 1;23(19):4390-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
  • PURPOSE: This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma.
  • PATIENTS AND METHODS: Patients had follicular lymphoma that had relapsed or failed to respond to primary therapy; the majority (90%) presented with stage III or IV disease.
  • CONCLUSION: The favorable safety profile of galiximab and evidence of single-agent biologic activity and dose-dependent pharmacokinetics support further evaluation of galiximab as a treatment for follicular lymphoma, possibly in combination with other lymphoma therapies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD80 / immunology. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Infection / complications. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994148.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD80; 0 / Antineoplastic Agents; 357613-77-5 / galiximab
  •  go-up   go-down


75. Andersen ES, Gerstoft J, Weis N: Reactivation of hepatitis D virus after chemotherapy for diffuse large B cell lymphoma despite lamivudine prophylaxis. Int J Hematol; 2010 Sep;92(2):378-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactivation of hepatitis D virus after chemotherapy for diffuse large B cell lymphoma despite lamivudine prophylaxis.
  • We describe a case of reactivation of hepatitis D virus (HDV) in a patient treated with chemotherapy for a diffuse large B cell lymphoma despite lamivudine prophylaxis.
  • This case suggests that previously cleared HDV should be considered when administering chemotherapy to patients with lymphoma.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hepatitis Delta Virus / physiology. Lymphoma, Large B-Cell, Diffuse / complications. Premedication / methods. Virus Activation / drug effects
  • [MeSH-minor] Adult. Humans. Lamivudine / therapeutic use. Male. Reverse Transcriptase Inhibitors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Rev Med Virol. 2001 Sep-Oct;11(5):287-99 [11590667.001]
  • [Cites] Hepatology. 2001 Aug;34(2):404-10 [11481626.001]
  • [Cites] Antivir Ther. 2008;13(1):97-102 [18389903.001]
  • [Cites] Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):31-40 [20051970.001]
  • [Cites] J Hepatol. 1991 Jan;12(1):64-9 [2007777.001]
  • [Cites] Am J Med. 2007 Dec;120(12):1034-41 [18060923.001]
  • [Cites] Liver Int. 2006 Sep;26(7):805-10 [16911462.001]
  • [Cites] J Virol. 1997 Mar;71(3):2241-51 [9032359.001]
  • [Cites] Hepatology. 1991 Jun;13(6):1052-6 [2050321.001]
  • [Cites] N Engl J Med. 1994 Jan 13;330(2):88-94 [8259188.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1740-9 [15188169.001]
  • (PMID = 20686876.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


76. Fernández Canal C, Campoamor Serrano M, García Alcalde Fernández ML: [Primary esophageal lymphoma in a acquired immunodeficiency syndrome: a case report]. An Med Interna; 2007 May;24(5):259-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary esophageal lymphoma in a acquired immunodeficiency syndrome: a case report].
  • [MeSH-major] Esophageal Neoplasms. Lymphoma, AIDS-Related. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Prednisone / administration & dosage. Remission Induction. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929393.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


77. Fischer L, Martus P, Weller M, Klasen HA, Rohden B, Röth A, Storek B, Hummel M, Nägele T, Thiel E, Korfel A: Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology; 2008 Sep 30;71(14):1102-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients.
  • BACKGROUND: The impact of meningeal dissemination in primary CNS lymphoma (PCNSL) is debated, and the reported frequency varies.
  • CONCLUSIONS: We found a low rate of meningeal dissemination in primary CNS lymphoma in this large prospective study.
  • [MeSH-major] Lymphoma / diagnosis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Neoplasm Metastasis / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Cell Count / statistics & numerical data. Combined Modality Therapy. Cytological Techniques / statistics & numerical data. Female. Humans. Immunoglobulin Heavy Chains / analysis. Immunoglobulin Heavy Chains / blood. Magnetic Resonance Imaging / statistics & numerical data. Male. Meninges / pathology. Middle Aged. Polymerase Chain Reaction / statistics & numerical data. Predictive Value of Tests. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824675.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


78. Besson C, Amiel C, Le-Pendeven C, Brice P, Fermé C, Carde P, Hermine O, Raphael M, Abel L, Nicolas JC: Positive correlation between Epstein-Barr virus viral load and anti-viral capsid immunoglobulin G titers determined for Hodgkin's lymphoma patients and their relatives. J Clin Microbiol; 2006 Jan;44(1):47-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive correlation between Epstein-Barr virus viral load and anti-viral capsid immunoglobulin G titers determined for Hodgkin's lymphoma patients and their relatives.
  • Here, we found that there was no correlation between VLo and either anti-EBV nuclear antigen type 1 or anti-early antigen immunoglobulin G (IgG) titer but that anti-viral capsid antigen (VCA) IgG titer increased with VLo in peripheral blood mononuclear cells in patients with Hodgkin's lymphoma (P = 3.10(-3)).
  • [MeSH-major] Antibodies, Viral / analysis. Capsid Proteins / immunology. Herpesvirus 4, Human / immunology. Hodgkin Disease / virology. Immunoglobulin G / analysis. Lymphoma / virology. Tumor Virus Infections / immunology
  • [MeSH-minor] Adolescent. Adult. Antigens, Viral / immunology. Female. Humans. Male. Viral Load

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Virol. 2002 Mar;66(3):360-9 [11793388.001]
  • [Cites] Br J Haematol. 2005 May;129(4):511-9 [15877733.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5419-28 [14662920.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] J Infect Dis. 1985 Jun;151(6):1150-3 [2987370.001]
  • [Cites] N Engl J Med. 1989 Mar 16;320(11):689-95 [2537928.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):801-4 [2172169.001]
  • [Cites] Blood. 1994 Aug 1;84(3):972-84 [8043879.001]
  • [Cites] Immunity. 1996 Aug;5(2):173-9 [8769480.001]
  • [Cites] J Med Virol. 2001 Nov;65(3):543-52 [11596092.001]
  • [Cites] Pediatr Pathol Lab Med. 1997 May-Jun;17(3):391-400 [9185219.001]
  • [Cites] J Med Virol. 1999 Apr;57(4):383-9 [10089051.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):442-8 [10404101.001]
  • [Cites] J Med Virol. 2005 Jan;75(1):59-69 [15543571.001]
  • [Cites] J Virol. 2005 Jan;79(2):1296-307 [15613356.001]
  • [Cites] AIDS. 2002 May 3;16(7):993-1001 [11953465.001]
  • (PMID = 16390946.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, Viral; 0 / Capsid Proteins; 0 / Immunoglobulin G
  • [Other-IDs] NLM/ PMC1351946
  •  go-up   go-down


79. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol; 2006 Apr 1;24(10):1582-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
  • PURPOSE: Advanced-stage follicular lymphoma is considered incurable.
  • This article analyzes five sequential cohorts of patients with stage IV follicular lymphoma treated between 1972 and 2002.
  • A proportional hazards analysis, and subset analyses using the follicular lymphoma international prognostic index (FLIPI) score were performed.
  • CONCLUSION: Evolving therapy, including the incorporation of biologic agents, has led to stepwise significant outcome improvements for patients with advanced-stage follicular lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575009.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Tang QL, Liu WP, Zhang WY, Yang F, He MX, Xia QJ, Li GD: [Expression of CYR61 and VEGF in extranodal nasal-type NK/T cell lymphoma and their significances]. Zhonghua Xue Ye Xue Za Zhi; 2006 Oct;27(10):661-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CYR61 and VEGF in extranodal nasal-type NK/T cell lymphoma and their significances].
  • OBJECTIVE: To investigate the expression of CYR61 and VEGF in extranodal nasal-type NK/T cell lymphoma and its significance.
  • METHODS: CYR61 mRNA and VEGF mRNA were detected by real-time fluorescence quantitative PCR method in 20 cases of extranodal nasal-type NK/T cell lymphoma.
  • CONCLUSION: In extranodal nasal-type NK/T cell lymphoma, the expression level of CYR61 and VEGF was changed and it may be of prognostic implication of
  • [MeSH-major] Immediate-Early Proteins / biosynthesis. Intercellular Signaling Peptides and Proteins / biosynthesis. Lymphoma, T-Cell / metabolism. Nose Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Cysteine-Rich Protein 61. Female. Humans. Killer Cells, Natural. Male. Middle Aged. Polymerase Chain Reaction. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343196.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CYR61 protein, human; 0 / Cysteine-Rich Protein 61; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


81. Ratner L, Grant C, Zimmerman B, Fritz J, Weil G, Denes A, Suresh R, Campbell N, Jacobson S, Lairmore M: Effect of treatment of Strongyloides infection on HTLV-1 expression in a patient with adult T-cell leukemia. Am J Hematol; 2007 Oct;82(10):929-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of treatment of Strongyloides infection on HTLV-1 expression in a patient with adult T-cell leukemia.
  • Human T-cell leukemia virus type 1 (HTLV-1) is associated with adult T-cell leukemia-lymphoma (ATLL) in about 5% of infected individuals.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hematol. 2003 Feb;77(2):164-70 [12627852.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2466-75 [11971181.001]
  • [Cites] Blood. 2002 Jan 1;99(1):88-94 [11756157.001]
  • [Cites] Am J Trop Med Hyg. 2006 Feb;74(2):246-9 [16474078.001]
  • [Cites] J Infect Dis. 2001 Jan 15;183(2):197-205 [11120926.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4954-60 [11042682.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2000 Sep-Oct;95(5):711-2 [10998221.001]
  • [Cites] Adv Cancer Res. 2003;89:69-132 [14587871.001]
  • [Cites] Clin Microbiol Rev. 2004 Jan;17(1):208-17 [14726461.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):4966-74 [15107832.001]
  • [Cites] Adv Cancer Res. 1989;53:33-72 [2552758.001]
  • [Cites] Clin Exp Immunol. 1990 Aug;81(2):207-11 [2143707.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Am J Med. 1992 Feb;92(2):202-8 [1543206.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):771-4 [7917938.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Parasite Immunol. 2004 Nov-Dec;26(11-12):487-97 [15771684.001]
  • [Cites] J Infect Dis. 2005 Feb 15;191(4):612-8 [15655786.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):394-402 [10096585.001]
  • [Cites] Am J Clin Pathol. 1997 Jan;107(1):81-7 [8980372.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):182-6 [8680890.001]
  • [Cites] J Infect Chemother. 2004 Dec;10(6):348-51 [15614460.001]
  • (PMID = 17617788.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100730-069003; United States / NCI NIH HHS / CA / CA100730-05; United States / NCI NIH HHS / CA / CA63417; United States / NCI NIH HHS / CA / CA10073; United States / NCI NIH HHS / CA / R01 CA063417; United States / NCI NIH HHS / CA / P01 CA100730-05; United States / NCI NIH HHS / CA / R01 CA105218; United States / NCI NIH HHS / CA / CA100730-069003; United States / NCI NIH HHS / CA / CA105218
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthelmintics; 0 / DNA, Viral; 0 / RNA, Viral; 70288-86-7 / Ivermectin
  • [Other-IDs] NLM/ NIHMS94116; NLM/ PMC2652703
  •  go-up   go-down


82. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W, Vellenga E: Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood; 2007 Jan 15;109(2):486-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.
  • This study was set up to demonstrate whether prognostic classification based on the secondary age-adjusted International Prognostic Index (sAA-IPI) for recurring aggressive non-Hodgkin lymphoma (NHL) or the prognostic score for recurring Hodgkin lymphoma (HL) can be improved by including the midtreatment results of fluorine-18-fluorodeoxy-glucose-positron emission tomography (FDG-PET).
  • Clinical data on patients with recurring lymphoma who were treated with second-line chemotherapy (DHAP-VIM-DHAP) followed by autologous stem cell transplantation (ASCT) were collected and combined with the results of FDG-PET performed before and after 2 cycles of reinduction chemotherapy.
  • Both secondary clinical risk score (P<.001) and FDG-PET response (P<.001) were independent predictive factors for the total evaluable group of patients with lymphoma and for patients with NHL alone.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Remission Induction. Risk Factors. Sensitivity and Specificity. Survival Rate. Transplantation, Autologous. Treatment Outcome


83. Janíková-Oborilová A, Mayer J, Dvorákova D, Mejstrík P, Navritíl M, Vásová I, Kren L, Matuska M: [Practical aspects and clinical value of t(14;18) monitoring in peripheral blood of the follicular lymphoma patients]. Cas Lek Cesk; 2007;146(4):374-81; discussion 381-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Practical aspects and clinical value of t(14;18) monitoring in peripheral blood of the follicular lymphoma patients].
  • BACKGROUND: Evaluation of practical value of monitoring t(14:18) in peripheral blood in follicular lymphoma.
  • METHODS AND RESULTS: t(14;18) was tested in 115 follicular lymphoma patients by methods: FISH, nested and multiplex PCR of blood, bone marrow and lymph node specimens.
  • CONCLUSIONS: t(14;18) is highly associated with follicular lymphoma.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Lymphoma, Follicular / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Polymerase Chain Reaction. Recurrence. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491248.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


84. Gayed I, Eskandari MF, McLaughlin P, Pro B, Diba R, Esmaeli B: Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging; 2007 Jul-Aug;38(4):319-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The clinical records of 16 consecutive patients with ocular adnexal lymphoma for whom pretreatment and posttreatment PET scans and corresponding computed tomography (CT) and magnetic resonance imaging (MRI) scans were available were compared.
  • In 1 patient with low-grade follicular lymphoma of the orbit, PET revealed an additional focus of lymphoma in the deltoid muscle that was missed on clinical examination and conventional radiography.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Orbital Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674923.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. Kimura A, Ueyama H, Kimura N, Fujimoto S, Kumamoto T: Progressive multifocal leukoencephalopathy in an HTLV-I carrier. Clin Neurol Neurosurg; 2006 Dec;108(8):768-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three years later, the patient developed lymphoma-type of adult T-cell leukemia, suggesting that HTLV-I carrier might be one of the underlying diseases of PML.
  • [MeSH-minor] Adult. Biopsy. Brain / pathology. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Frontal Lobe / pathology. Frontal Lobe / virology. HTLV-I Antigens / blood. Humans. Injections, Intramuscular. Interferon-alpha / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymph Nodes / pathology. Magnetic Resonance Imaging. Oligodendroglia / pathology. Oligodendroglia / virology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257112.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / HTLV-I Antigens; 0 / Interferon-alpha
  •  go-up   go-down


86. Cheng XC, Li HC, Zhang R, Tan J: [Expression of the neopterin in serum and urine of the patients with non-Hodgkin's lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun;13(3):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of the neopterin in serum and urine of the patients with non-Hodgkin's lymphoma].
  • To explore the relationship between the experimental parameters including the neopterin (Npt), LDH and beta(2)-MG concentrations in serum or urine and the therapeutic effect on non-Hodgkin's lymphoma (NHL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972138.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / beta 2-Microglobulin; 670-65-5 / Neopterin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


87. Pullarkat VA, Medeiros LJ, Brynes RK: Body cavity-based presentation of natural killer cell lymphoma. Leuk Lymphoma; 2005 Feb;46(2):293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body cavity-based presentation of natural killer cell lymphoma.
  • We describe an unusual case of a 31-year-old Mexican woman who presented with pleural and peritoneal effusions involved by Epstein-Barr virus-positive non-Hodgkin's lymphoma of natural killer (NK)-cell lineage.
  • Thus, this case clinically mimicked body cavity-based lymphoma.
  • Extranodal NK/T-cell lymphoma of nasal type is the current designation for these neoplasms in the recently proposed World Health Organization classification of lymphoid neoplasms.
  • These tumors previously have been referred to many other names, including lethal midline granuloma, midline malignant reticulosis, polymorphic reticulosis, angiocentric immunoproliferative lesion, and angiocentric lymphoma.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology. Nose Neoplasms / diagnosis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Herpesvirus 4, Human / isolation & purification. Humans. Pleural Cavity / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621817.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Toulza F, Nosaka K, Takiguchi M, Pagliuca T, Mitsuya H, Tanaka Y, Taylor GP, Bangham CR: FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. Int J Cancer; 2009 Nov 15;125(10):2375-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia.
  • Human T-lymphotropic virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia/lymphoma (ATLL).
  • [MeSH-major] Forkhead Transcription Factors / metabolism. HTLV-I Infections / immunology. Human T-lymphotropic virus 1 / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adult. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Cell Proliferation. Chronic Disease. Female. Flow Cytometry. Follow-Up Studies. Humans. Longitudinal Studies. Male. Middle Aged. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544530.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


89. Tham IW, Lee KM, Yap SP, Loong SL: Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head Neck; 2006 Feb;28(2):126-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy.
  • BACKGROUND: This study reviews the outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated at the Therapeutic Radiology Department, National Cancer Centre, Singapore, from 1997 to 2003.
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell / radiotherapy. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Survival Rate. Treatment Failure

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc.
  • (PMID = 16240328.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Cai Y, Sun XF, Yan SL, Zhen ZJ, Xia Y, Ling JY: Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma. Chin J Cancer; 2010 Mar;29(3):312-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma.
  • BACKGROUND AND OBJECTIVE: Precursor T lymphoblastic lymphoma (T-LBL) is a highly aggressive lymphoma.
  • But the remission rate and the 2-year overall survival rate were significantly lower in adult patients with myeloid antigen expression than in patients without it.
  • CONCLUSION: Myeloid antigen expression is a predictor of a poor response to chemotherapy, and adverse prognostic factor in adult T-LBL, but not in children with T-LBL.
  • [MeSH-major] Antigens, Differentiation, Myelomonocytic / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Transcription Factors / metabolism
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Adult. Age Factors. Aged. Antigens, CD7 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Child. Cyclin D3 / metabolism. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisone / therapeutic use. Proportional Hazards Models. Remission Induction. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193116.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD7; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CCND3 protein, human; 0 / Cyclin D3; 0 / MNDA protein, human; 0 / Transcription Factors; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol; EPOCH protocol
  •  go-up   go-down


91. Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, Shaw BE, McMillan A, Gonzalez J, Ho A, Mufti GJ, Pagliuca A: Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol; 2008 Apr;141(2):235-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
  • The role of haematopoietic stem cell transplantation (HSCT) in relapsed follicular lymphoma remains controversial.
  • This study analysed 126 patients with relapsed, advanced stage follicular lymphoma who received BEAM (BCNU [carmustine], cytarabine, etoposide, melphalan)-alemtuzumab allogeneic HSCT (BEAM-allo) (n = 44) or BEAM-autologous HSCT (BEAM-auto) (n = 82).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Follicular / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Antibodies, Monoclonal, Humanized. Carmustine / adverse effects. Carmustine / therapeutic use. Cytarabine / adverse effects. Cytarabine / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Follow-Up Studies. Graft Survival. Graft vs Host Disease / etiology. Hematopoietic Stem Cell Mobilization / methods. Histocompatibility Testing. Humans. Male. Melphalan / adverse effects. Melphalan / therapeutic use. Middle Aged. Retrospective Studies. Transplantation Chimera. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318762.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 04079A1RDZ / Cytarabine; 3A189DH42V / alemtuzumab; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  •  go-up   go-down


92. Sorá F, Piccirillo N, Chiusolo P, Laurenti L, Marra R, Bartolozzi F, Leone G, Sica S: Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma. Cancer; 2006 Feb 15;106(4):859-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma.
  • BACKGROUND: The objective of the current study was to evaluate a salvage chemotherapy regimen consisting of mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone (MiCMA) for the treatment of patients with primary refractory or recurrent non-Hodgkin lymphoma (NHL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Cytarabine / administration & dosage. Drug Resistance, Neoplasm. Female. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Recurrence. Salvage Therapy. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16419074.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BG3F62OND5 / Carboplatin; BZ114NVM5P / Mitoxantrone; X4W7ZR7023 / Methylprednisolone; MiCMA protocol
  •  go-up   go-down


93. Fukushima N, Satoh T, Sueoka N, Sato A, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N, Sano M, Tokunaga O, Sueoka E: Clinico-pathological characteristics of p63 expression in B-cell lymphoma. Cancer Sci; 2006 Oct;97(10):1050-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathological characteristics of p63 expression in B-cell lymphoma.
  • A member of the family of p53-related genes, p63 plays a role in regulating epithelial proliferation and differentiation programs, but the pathological and clinical meaning of p63 in B-cell lymphoma has not been elucidated.
  • RT-PCR revealed that TAp63alpha-type transcripts, a possible negative regulator of transcriptional activation of p21 promoter, were major transcripts in B-cell lymphoma tissues.
  • [MeSH-major] DNA-Binding Proteins / analysis. Lymphoma, B-Cell / diagnosis. Trans-Activators / analysis. Tumor Suppressor Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alternative Splicing. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / analysis. Transcription Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918993.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


94. Balwierz W, Czogała M, Czepko E: [Anaplastic large cell lymphoma associated with hemophagocytic lymphohistiocytosis: a case report and review of the literature]. Przegl Lek; 2010;67(6):436-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic large cell lymphoma associated with hemophagocytic lymphohistiocytosis: a case report and review of the literature].
  • Here we present a case report of a 14 years old boy diagnosed with HLH before recognition of anaplastic large cell lymphoma (ALCL).
  • First-line therapy, according to protocol for this type of lymphoma, was introduced.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphohistiocytosis, Hemophagocytic / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Disease Progression. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Remission Induction. Stem Cell Transplantation


95. Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J: Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. Leuk Lymphoma; 2007 Jun;48(6):1092-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
  • The aim of this study was to determine the feasibility, efficacy and toxicity of the combined therapy consisting of cladribine (2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in patients with refractory or relapsed non-Hodgkin's lymphoma (NHL).
  • Thirty six patients, 14 with mantle cell lymphoma (MCL), 10 with diffuse large B-cell lymphoma (DLBCL), 5 with follicular lymphoma (FL), 3 with small lymphocytic lymphoma (SLL), and 4 with T-cell lymphoma were enrolled to the study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cladribine / adverse effects. Cladribine / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Feasibility Studies. Female. Humans. Male. Middle Aged. Mitoxantrone / adverse effects. Mitoxantrone / therapeutic use. Salvage Therapy / adverse effects. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577772.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; CMC protocol 2
  •  go-up   go-down


96. Reman O, Pigneux A, Huguet F, Vey N, Delannoy A, Fegueux N, de Botton S, Stamatoullas A, Tournilhac O, Buzyn A, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Fière D, Dombret H, Thomas X, GET-LALA group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res; 2008 Nov;32(11):1741-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group.
  • Outcome of adult acute lymphoblastic leukemia (ALL) with central nervous system (CNS) involvement is not clearly defined.
  • CNS leukemia in adult ALL is uncommon at diagnosis as well as at the time of first relapse.
  • CNS leukemia at first relapse remains of similar poor prognosis than all other adult ALL in first relapse.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508120.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


97. Fesler MJ, Nguyen NC, Petruska PJ: Modified escalated BEACOPP as salvage chemotherapy in classic Hodgkin lymphoma. Int J Hematol; 2010 Jul;92(1):211-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified escalated BEACOPP as salvage chemotherapy in classic Hodgkin lymphoma.
  • [MeSH-minor] Adult. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Male. Prednisone / therapeutic use. Procarbazine / therapeutic use. Salvage Therapy / methods. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1998 Nov;22(9):853-7 [9827812.001]
  • [Cites] Leuk Lymphoma. 2009 Nov;50(11):1803-8 [19860621.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1253-61 [18940680.001]
  • [Cites] Leuk Lymphoma. 2009 Nov;50(11):1733-4 [19883301.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:245-51 [16304388.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):143-8 [9093722.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4548-54 [19704068.001]
  • (PMID = 20582576.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


98. Assaf C, Gellrich S, Steinhoff M, Nashan D, Weisse F, Dippel E, Coors E, Stein A, Gollin P, Henke U, Adam-Murati S, Koch A, Klemke CD, Stadler R, Sterry W: Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges; 2007 Aug;5(8):662-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG).
  • They manifest themselves on the skin and are the second most frequent group of non-Hodgkin lymphoma (NHL) following gastrointestinal lymphomas.
  • The epidemiology of cutaneous lymphomas in Germany is compared to other national or regional lymphoma registries.
  • [MeSH-major] Lymphoma / epidemiology. Registries. Risk Assessment / methods. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dermatology / statistics & numerical data. Female. Germany / epidemiology. Humans. Male. Middle Aged. Prevalence. Risk Factors. Societies, Medical

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659039.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


99. Orciuolo E, Buda G, Sordi E, Baraté C, Galimberti S, Ciancia E, Petrini M: 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res; 2010 Feb;34(2):184-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Cladribine / administration & dosage. Lymphoma, B-Cell, Marginal Zone / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Remission Induction / methods. Rituximab. Survival Rate. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19414190.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


100. Wang FH, Li YH, Zeng J, Rao HL, Xia ZJ, Sun XF, Huang HQ, Lin TY, Jiang WQ, Guan ZZ: Clinical analysis of primary systemic anaplastic large cell lymphoma: a report of 57 cases. Ai Zheng; 2009 Jan;28(1):49-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of primary systemic anaplastic large cell lymphoma: a report of 57 cases.
  • BACKGROUND AND OBJECTIVE: The clinical characteristics and prognosis of primary systemic anaplastic large cell lymphoma (ALCL) are various according to different reports.
  • Anaplastic lymphoma kinase (ALK), a specific marker of primary systemic ALCL, is related with its clinical characteristics and prognosis.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / drug therapy. Protein-Tyrosine Kinases / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor Protein-Tyrosine Kinases. Survival Rate

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448428.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down






Advertisement